Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis invon Hippel-Lindau disease

Human Molecular Genetics

Volumn 10, Issue 10, 2001, Pages 1029-1038

  Clifford, Steven C ^a,d   Cockman, Matthew E ^b   Smallwood, Alan C ^a   Mole, David R ^b   Woodward, Emma R ^c,e   Maxwell, Patrick H ^b   Ratcliffe, Peter J ^b   Maher, Eamonn R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CUL2 PROTEIN; ELONGIN B; ELONGIN C; FIBRONECTIN; GENE PRODUCT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE PREDISPOSITION; GENE FUNCTION; GENE MUTATION; HEMANGIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

ADRENAL GLAND NEOPLASMS; ALLELES; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; CLONING, MOLECULAR; DNA-BINDING PROTEINS; DOWN-REGULATION; GENOTYPE; HEMANGIOBLASTOMA; HIPPEL-LINDAU DISEASE; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; LIGASES; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PHENOTYPE; PHEOCHROMOCYTOMA; PROTEIN BINDING; PROTEINS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0035339044     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Maher, E.R., Yates, J.R.W., Harries, R., Benjamin, C., Harris, R. and Ferguson-Smith, M.A. (1990) Clinical features and natural history of von Hippel-Lindau disease. Q. J. Med., 77, 1151-1163.
2. Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.M., Orcutt, ML., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L. et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science, 260, 1317-1320.
3. Kaelin, W.O.,Jr and Maher, E.R. (1998) The VHL tumour-suppressor gene paradigm. Trends Genet., 14, 423-426.
4. Foster, K., Prowse, A., van den Berg, A., Fleming, S., Hulsbeek, M.M., Crossey, P.A., Richards, F.M., Cairns, P., Affara, N.A., Ferguson-Smith, M.A. et al. (1994) Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet., 3, 2169-2173.
5. Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.M. et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet., 7, 85-90.
6. Herman, J.G., Latif, F., Weng, Y., Lerman, M.I., Zhar, B., Liu, S., Samid, D., Duan, D.S., Gnarra, J.R., Linehan, W.M. et al. (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA, 91, 9700-9704.
7. Clifford, S.C., Prowse, A.M., Affara, N.A., Buys, C.H. and Maher, E.R. (1998) Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer, 22, 200-209.
8. Chen, F., Kishida, T., Duh, F.M., Renbaum, P., Orcutt, M.L., Schmidt, L. and Zbar, B. (1995) Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res., 55, 4804-4807.
9. Iliopoulos, O., Kibel, A., Gray, S. and Kaelin, W.G.,Jr. (1995) Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med., 1, 822-826.
10. Siemeister; G., Weindel, K., Mohrs, K., Barleon, B., Martiny-Baron, G. and Marme, D. (1996) Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res., 56, 2299-2301.
11. Gnarra, J.R., Zhou, S., Merrill, M.J., Wagner, J.R., Krumm, A., Papavassiliou, E., Oldfield, E.H., Klausner, R.D. and Linehan. W.M. (1996). Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl Acad. Sci. USA, 93, 10589-10594.
12. Iliopoulos, O., Levy, A.P., Jiung, C., Kaelin, W.G.,Jr and Goldberg, M.A. (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA, 93, 10595-10599.
13. Pause, A., Lee, S., Worrell, R.A., Chen, D.Y., Burgess, W.H., Linehan, W.M. and Klausner, R.D. (1997) The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl Acad. Sci. USA, 94, 2156-2161.
14. Lonergan, K.M., Iliopoulos, O., Ohh, M., Kamura, T., Conaway, R.C., Conaway, J.W. and Kaelin, W.G.,Jr. (1998) Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol., 18, 732-741.
15. Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R. and Ratcliffe, P.J. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399, 271-275.
16. Stebbins, C.E., Kaelin, W.G.,Jr and Pavletich, N.P. (1999) Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science, 284, 455-461.
17. Cockman, M.E., Masson, N., Mole, D.R., Jaakkola, P., Chang, G.W., Clifford, S.C., Maher, E.R., Pugh, C.W., Ratcliffe, P.J. and Maxwell, P.H. (2000) Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem., 275, 25733-25741.
18. Kamura, T., Sato, S., Iwai, K., Czyzyk-Krzeska, M., Conaway, R.C. and Conaway, J.W. (2000) Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl Acad. Sci USA, 97, 10430-10435.
19. Ohh, M., Park, C.W., Ivan, M., Hoffman, M.A., Kim, T.Y., Huang, L.E., Pavletich, N., Chau, V. and Kaelin, W.G. (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nature Cell. Biol., 2, 423-427.
20. Pause, A., Lee, S., Lonergan, K.M. and Klausner, R.D. (1998) The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl Acad. Sci. USA, 95, 993-998.
21. Ohh, M., Yauch, R.L., Lonergan, K.M., Whaley, J.M., Stemmer-Ruchamimov, A.O., Louis, D.N., Gavin, B.J., Kley, N., Kaelin, W.G., Jr and Iliopoulos, O. (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell., 1, 959-968,
22. Gnarra, J.R., Zhou, S., Merrill, M.J., Wagner, J.R., Krumm, A., Papavassiliou, E., Oldfield, E.H., Klausner, R.D. and Linehan, W.M. (1996) Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl Acad. Sci. USA, 93, 10589-10594.
23. Levy, A.P., Levy, N.S. and Goldberg, M.A. (1996) Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulution by the von Hippel-Lindau protein. J. Biol. Chem., 271, 25492-25497.
24. Knebelmann, B., Ananth, S., Cohen, H.T. and Sukhatme, V.P. (1998) Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res., 58, 226-231.
25. Brauch, H., Kishida, T., Glavac, D., Chen, F., Pausch, F., Hofler, H., Latif, F., Lerman, M.I., Zbar, B. and Neumann, HP. (1995) von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum. Genet. 95, 551-556.
26. Neumann, H.P., Eng, C., Mulligan, L.M., Glavac, D., Zauner, I., Ponder, B.A., Crossey, P.A., Maher, E.R. and Brauch, H. (1995) Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. J. Am. Med. Assoc., 274, 1149-1151.
27. Iliopoulos, O., Ohh, M. and Kaelin, W.G., Jr. (1998) pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl Acad. Sci. USA, 95, 11661-11666.
28. Schoenfeld, A., Davidowitz, E.J. and Burk, R.D. (1998) A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl Acad. Sci. USA, 95, 8817-8822.
29. Duan, D.R., Pause, A., Burgess, W.H., Aso, T., Chen, D.Y., Garrett, K.P., Conaway, R.C., Conaway, J.W., Linehan, W.M. and Klausner, R.D. (1995) Inhibition of transcription elongation by the VHL tumor suppressor protein. Science, 269, 1402-1406.
30. Kibel, A., Iliopoulos, O., DeCaprio, J.A. and Kaelin, W.G.,Jr. (1995) Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science, 269, 1444-1446.
31. Webster, A.R., Richards, F.M., MacRonald, F.E., Moore, A.T. and Maher, E.R. (1998) An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am. J. Hum. Genet. 63, 1025-1035.
32. Crossey, P.A., Richards, F.M., Foster, K., Green, J.S., Prowse, A., Latif, F., Lerman, M.I., Zbar, B., Affara, N.A., Ferguson-Smith, M.A. and Maher, E.R. (1994) Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum. Mol. Genet., 3, 1303-1308.
33. Maher, E.R., Webster, A.R., Richards, F.M., Green, J.S., Crossey, P.A., Payne, S.J. and Moore, A.T. (1996) Phenotypic expression in von Hippel-Lindau disease: Correlations with germline VHL gene mutations. J. Med. Genet., 33, 328-332.
34. Zbar, B., Kishida, T., Chen, F., Schmidt, L., Maher, E.R., Richards, F.M., Crossey, P.A., Webster, A.R., Affara, N.A., Ferguson-Smith, M.A. et al. (1996) Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe and Japan. Hum. Mutat., 8, 348-357.
35. Gnarra, J.R., Ward, J.M., Porter, F.D., Wagner, J.R., Devor, D.E., Grinberg, A., Emmert-Buck, M.R., Westphal, H., Klausner, R.D. and Linehan, W.M. (1997) Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl Acad. Sci. USA, 94, 9102-9107.
36. Haase, V.H., Glickman, J.N., Socolovsky, M. and Jaenisch, R. (2001) Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl Acad. Sci. USA, 98, 1583-1588.
37. Hoffman, M.A., Ohh, M., Yang, H., Klco, J.M., Ivan, M. and Kaelin, W.G.,Jr (2001) von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet., 10, 1019-1027.
38. Wykoff, C.C., Pugh, C.W., Maxwell, P.H., Harris, A.L. and Ratcliffe, P.J. (2000) Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumor suppressor by mRNA differential expression profiling. Oncogene, 19, 6297-6305.
39. Takahashi, Y., Takahashi, S., Shiga, Y., Yoshimi, T. and Miura, T. (2000) Hypoxic induction of prolyl 4-hydroxylase α (I) in cultured cells. J. Biol. Chem., 275, 14139-14146.
40. Iwai, K., Yamanaka, K., Kamura, T., Minato, N., Conaway, R.C., Canaway, J.W., Klausner, R.D. and Pause, A. (1999) Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl Acad. Sci. USA, 96, 12436-12441.
41. Wiesener, M.S., Turley, H., Allen, W.E., Willam, C., Eckardt, K.U., Talks, K.L., Wood, S.M., Gatter, K.C., Harris, A.L., Pugh, C.W. et al. (1998) Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-α. Blood, 92, 2260-2268.